Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

A new study finds that patients with systemic sclerosis (SSc) have a significantly higher risk of cancer-related mortality, ...

which is in Phase I clinical trial to treat non-small cell lung cancer. Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily ...

Dying from colon cancer in the end stage means that treatments are no longer working or need to be stopped due to side effects. The cancer has spread throughout the body, and the condition is ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Archaeologists in Israel have discovered five burials in a cave belonging to an enigmatic human lineage that suggest this group shared aspects of its lifestyle, technology and burial customs with ...

There are 18 classes in Arcane Lineage, which can be chosen after reaching base level 5+ and improved after reaching level 15+. Each class has its distinct features, which I’ll cover in this ...

CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...